<![CDATA[Zealand Pharma — November 2021]]>Velkommen til den Zealand Pharma chat. 🙂

]]>https://dev.proinvestor.com/forum/topic/400801/zealand-pharma-november-2021RSS for NodeSat, 06 Jun 2026 09:03:36 GMTSun, 14 Nov 2021 06:02:44 GMT60<![CDATA[Reply to Zealand Pharma — November 2021 on Tue, 30 Nov 2021 22:54:21 GMT]]>Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021

]]>https://dev.proinvestor.com/forum/post/8026621https://dev.proinvestor.com/forum/post/8026621Tue, 30 Nov 2021 22:54:21 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 23:39:14 GMT]]>Credit Suisse som storaktionær? Ja, hvorfor ikke. Hvis de kan spotte et potentiale og en pris, der danner base for en investering, er de velkommen i familien.

]]>https://dev.proinvestor.com/forum/post/8026624https://dev.proinvestor.com/forum/post/8026624Mon, 29 Nov 2021 23:39:14 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 14:58:40 GMT]]>@Svingtraderen - tak selv 🙂

]]>https://dev.proinvestor.com/forum/post/8026618https://dev.proinvestor.com/forum/post/8026618Mon, 29 Nov 2021 14:58:40 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 14:58:15 GMT]]>@TopPhama - Orphan Drug Designation

"Glepaglutide is a long-acting GLP-2 analog in development for the treatment of SBS. It was granted orphan drug designation by the U.S. FDA and is currently being studied in Phase 3 clinical trials"

https://www.zealandpharma.com/glepaglutide

]]>https://dev.proinvestor.com/forum/post/8026625https://dev.proinvestor.com/forum/post/8026625Mon, 29 Nov 2021 14:58:15 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 14:36:00 GMT]]>Du er hurtig - tak

]]>https://dev.proinvestor.com/forum/post/8026623https://dev.proinvestor.com/forum/post/8026623Mon, 29 Nov 2021 14:36:00 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 14:33:41 GMT]]>"Following the acquisition of shares in Zealand, Credit Suisse Group AG controls more than 5% of the total voting rights in Zealand and Credit Suisse Group AG holds more than 5% of the total share capital of Zealand."

]]>https://dev.proinvestor.com/forum/post/8026617https://dev.proinvestor.com/forum/post/8026617Mon, 29 Nov 2021 14:33:41 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 14:32:47 GMT]]>Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021

https://www.globenewswire.com/news-release/2021/11/29/2342335/0/en/Zealand-Pharma-major-shareholder-announcement-Credit-Suisse-Group-AG-2021.html

]]>https://dev.proinvestor.com/forum/post/8026622https://dev.proinvestor.com/forum/post/8026622Mon, 29 Nov 2021 14:32:47 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 14:32:38 GMT]]>F
ra analysen Q3: FDA har tildelt orphan drug designation, hvilket giver skattefordele, kan give en længere årrække med eksklusivitet
efter en produktgodkendelse, udstedelse af en Priority Review Voucher, statslige tilskud m.m. Der er virkelig behov for nyskabelse til
gavn for de berørte patienter, og glepaglutide kan blive en game-changer

]]>https://dev.proinvestor.com/forum/post/8026614https://dev.proinvestor.com/forum/post/8026614Mon, 29 Nov 2021 14:32:38 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 14:31:43 GMT]]>hej exitnu kan det ikke passe at Zealand Parma har en Priority Review Voucher?

]]>https://dev.proinvestor.com/forum/post/8026616https://dev.proinvestor.com/forum/post/8026616Mon, 29 Nov 2021 14:31:43 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 13:36:53 GMT]]>Salget af Gvoke er ved at komme op i fart, monstro at Zegalogue også finder sin plads i det voksende nødpen-marked.

]]>https://dev.proinvestor.com/forum/post/8026619https://dev.proinvestor.com/forum/post/8026619Mon, 29 Nov 2021 13:36:53 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 13:36:25 GMT]]>Xeris Biopharma q3 2021: "Gvoke: Third quarter 2021 prescriptions topped 27,000 for the first time, growing more than 28% from the prior quarter and 95% compared to the same period in 2020. Gvoke’s NRx share of the retail glucagon market grew to approximately 18% during the third quarter. Gvoke YTD revenue more than doubled to $27.9 million when compared to the same nine-month period in 2020."

]]>https://dev.proinvestor.com/forum/post/8026615https://dev.proinvestor.com/forum/post/8026615Mon, 29 Nov 2021 13:36:25 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 12:59:39 GMT]]>Det er selvfølgelig ikke sikkert at Danske Bank og Nordea og har ret i deres antagelser, men måske en ide at tage bestik og sagte sigte og sætte kursen 🙂 🙂

]]>https://dev.proinvestor.com/forum/post/8026611https://dev.proinvestor.com/forum/post/8026611Mon, 29 Nov 2021 12:59:39 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 12:59:25 GMT]]>"Danske Bank har sænket kursmålet for Zealand Pharma-aktien til 250 kr. mod tidligere 310 kr. Banken fastholder imidlertid sin køb-anbefaling på aktien."

"De lavere forventninger har ført til en lignende reaktion hos Nordea. Banken sænkede torsdag sit kursmål for den danske biotekaktie – fra 280 kr. til 254 kr. Nordea fastholder dog ligesom Danske Bank sin købsanbefaling på aktien."

]]>https://dev.proinvestor.com/forum/post/8026613https://dev.proinvestor.com/forum/post/8026613Mon, 29 Nov 2021 12:59:25 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 12:51:45 GMT]]>Og så vil jeg gerne lige gentage: at påtage sig en shortposition er det samme som at have og gå med vand i en spand med hul i.

"Zealand Pharma-aktien er hamret ned – gemmer på mulig kursstigning på 40 pct."

Link Preview Image
Zealand Pharma-aktien er hamret ned – gemmer på mulig kursstigning på 40 pct.

favicon

Euroinvestor (www.euroinvestor.dk)

"Det var den mest shortede danske aktie i oktober"

https://www.euroinvestor.dk/nyheder/det-var-den-mest-shortede-danske-aktie-i-oktober

]]>https://dev.proinvestor.com/forum/post/8026610https://dev.proinvestor.com/forum/post/8026610Mon, 29 Nov 2021 12:51:45 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 12:45:53 GMT]]>Shorts i flertal, samt tankestregen binder kurs 140,1 og 2,03 % sammen.

Der er ikke "sat shorts" (flere positioner på i alt 2,03 %) på kurs 140,1, men en enkelt SHORTposition af Voleon Capital Management den 25. november på i alt 0.5%.

God dag.

]]>https://dev.proinvestor.com/forum/post/8026608https://dev.proinvestor.com/forum/post/8026608Mon, 29 Nov 2021 12:45:53 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 09:29:57 GMT]]>Det er vi så ikke enige i. Når der bliver responderet med en bemærkning om, at det er et falsum, ser jeg min(e) bemærkninger helt på sin plads, når integritet i dette forum skal vogtes. Tak for din vurdering og forsat god dag.

]]>https://dev.proinvestor.com/forum/post/8026606https://dev.proinvestor.com/forum/post/8026606Mon, 29 Nov 2021 09:29:57 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 09:15:09 GMT]]>Tror de fleste almindeligt begavede forstår hvad johnlau skriver. lli du kan blot lade være med at læse hans indlæg, hvis du ikke forstår dem.

]]>https://dev.proinvestor.com/forum/post/8026605https://dev.proinvestor.com/forum/post/8026605Mon, 29 Nov 2021 09:15:09 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 01:19:35 GMT]]>@10:57 oversat til følgende: Der er sat shortposition i kurs 140,1. Shortpositioner på min. 0,5 %, udgør pt. 2,03 % af den samlede aktiekapital. Måske samme antal procenter på positioner mindre end 0,5 % af kapitalen?

]]>https://dev.proinvestor.com/forum/post/8026620https://dev.proinvestor.com/forum/post/8026620Mon, 29 Nov 2021 01:19:35 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 01:18:18 GMT]]>Jeg tillader mig at oversætte @Johnlau ' indlæg, så det giver mening for andre.

]]>https://dev.proinvestor.com/forum/post/8026602https://dev.proinvestor.com/forum/post/8026602Mon, 29 Nov 2021 01:18:18 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 01:16:05 GMT]]>Kan du ikke gøre dig lidt umage, når du skriver herinde eller sende et kontantbidrag til Proinvestor, så du i det mindste bidrager lidt til dette forum.

]]>https://dev.proinvestor.com/forum/post/8026604https://dev.proinvestor.com/forum/post/8026604Mon, 29 Nov 2021 01:16:05 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Mon, 29 Nov 2021 01:13:58 GMT]]>@Johnlau. Kan du ikke anvende et punktum eller 2 i dit næste indlæg og måske et komma. Du har 3 afsnit og det er svært at læse, hvilke afsnit der skal læses sammen med andre og hvilke afsnit der skal så alene. De fleste havde med fordel sat et punkt, så det fremgik tydligt.

]]>https://dev.proinvestor.com/forum/post/8026609https://dev.proinvestor.com/forum/post/8026609Mon, 29 Nov 2021 01:13:58 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Sun, 28 Nov 2021 10:38:21 GMT]]>Desværre et falsum igen.

]]>https://dev.proinvestor.com/forum/post/8026603https://dev.proinvestor.com/forum/post/8026603Sun, 28 Nov 2021 10:38:21 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Fri, 26 Nov 2021 06:17:38 GMT]]>Banditterne kender ders besøgstid 🙂 🙂

]]>https://dev.proinvestor.com/forum/post/8026607https://dev.proinvestor.com/forum/post/8026607Fri, 26 Nov 2021 06:17:38 GMT<![CDATA[Reply to Zealand Pharma — November 2021 on Fri, 26 Nov 2021 04:24:54 GMT]]>Zealand Pharma Short Position Initiated By Voleon Capital Management https://www.proinvestor.com/investornyt/741054/zealand-pharma-short-position-initiated-by-voleon-capital-management

]]>https://dev.proinvestor.com/forum/post/8026599https://dev.proinvestor.com/forum/post/8026599Fri, 26 Nov 2021 04:24:54 GMT